Afatinib Dimaleate Entèmedyè CAS 314771-88-5 Pite> 99.0% (HPLC) Faktori
Ruifu Chimik Pwovizyon pou Entèmedyè nan Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino) acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Asid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Asid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-yon sèl CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Non Chimik | (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine |
Sinonim | N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[(3S)-oxolan-3-yl]oxyquinazolin-4-Amine;7-((S)-Tetrahydrofuran-3-yloxy)-4-(3-Chloro-4-Fluorophenyl)amino-6-Nitroquinazoline;Afatinib enpurte |
Nimewo CAS | 314771-88-5 |
Nimewo CAT | RF-PI2027 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C18H14ClFN4O4 |
Pwa molekilè | 404,78 |
Dansite | 1.534±0.060 g/cm3 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Jòn a limyè jòn poud |
Pite / Metòd analiz | >99.0% (HPLC) |
Pèt sou siye | <0.50% |
Enpurte endividyèl | <0.50% |
Enpurte total | <1.00% |
Metal lou | ≤20ppm |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan Afatinib Dimaleate (CAS: 850140-73-7) |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine (CAS: 314771-88-5) yo itilize nan preparasyon Afatinib Dimaleate (CAS: 850140-73-7).Afatinib se yon inovatè dwòg sib anti-kansè, yon nouvo jenerasyon dwòg sib oral, premye dwòg sib anti-kansè nan mond lan ki irevokabl mare nan fanmi an ErbB, epi li pi efikas ak vize Bloke siyal la ki deklanche kwasans selil kansè yo. , diminye oswa retade pwopagasyon selil kansè yo.Afatinib fè pati yon klas nan dwòg ke yo rekonèt kòm inibitè tirozin kinaz.Li travay pa bloke fonksyon an nan de pwoteyin ki gen rapò sere, reseptè a faktè kwasans epidèm (EGFR) ak reseptè a faktè kwasans epidèm imen 2 (HER2).Itilize pou tretman premye liy pasyan ki gen kansè nan poumon metastatik ki pa ti selil.Afatinib se yon inovatè dwòg sib anti-kansè, yon nouvo jenerasyon dwòg sib oral, premye dwòg sib anti-kansè nan mond lan ki irevokabl mare nan fanmi an ErbB, epi li pi efikas ak vize Bloke siyal la ki deklanche kwasans selil kansè yo. , diminye oswa retade pwopagasyon selil kansè yo.